BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+0.51%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.85B
AUM Growth
+$9.85B
(-3.8%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-1.35%
Top 10 Holdings %
Top 10 Hldgs %
29.91%
Holding
226
New
13
Increased
56
Reduced
57
Closed
7
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$52.6M |
| 2 |
Revolution Medicines
RVMD
|
$44.1M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$37.4M |
| 4 |
Fate Therapeutics
FATE
|
$37M |
| 5 |
AMED
Amedisys
AMED
|
$36.1M |
Top Sells
| 1 |
Moderna
MRNA
|
$314M |
| 2 |
Halozyme
HALO
|
$53M |
| 3 |
Charles River Laboratories
CRL
|
$47.4M |
| 4 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$38M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$30.8M |
Sector Composition
| 1 | Healthcare | 96.84% |
| 2 | Industrials | 0.82% |
| 3 | Technology | 0.59% |
| 4 | Financials | 0.04% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Becton Dickinson
BDX
$54.3B
| $112M | 1.14% |
455,572
-5,393
| -1% | -$1.33M |
|
27
Stryker
SYK
$149B
| $111M | 1.13% |
422,332
+77,818
| +23% | +$20.5M |
|
28
CRISPR Therapeutics
CRSP
$4.82B
| $109M | 1.11% |
974,684
+7,800
| +0.8% | +$873K |
|
29
Insulet
PODD
$24.2B
| $109M | 1.1% |
382,994
+60,875
| +19% | +$17.3M |
|
|
AXNX
30
DELISTED
Axonics, Inc. Common Stock
AXNX
| $105M | 1.06% |
1,608,794
-121,677
| -7% | -$7.92M |
|
31
Align Technology
ALGN
$9.59B
| $104M | 1.06% |
157,031
+261
| +0.2% | +$174K |
|
32
Jazz Pharmaceuticals
JAZZ
$7.99B
| $100M | 1.02% |
769,238
+224,488
| +41% | +$29.2M |
|
33
Edwards Lifesciences
EW
$47.7B
| $98.5M | 1% |
869,951
-20,305
| -2% | -$2.3M |
|
34
Inspire Medical Systems
INSP
$2.53B
| $98.1M | 1% |
421,058
+47,832
| +13% | +$11.1M |
|
|
RDUS
35
DELISTED
Radius Health, Inc.
RDUS
| $96.4M | 0.98% |
7,768,714
+237,300
| +3% | +$2.94M |
|
|
SWAV
36
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $95.6M | 0.97% |
464,247
-52,668
| -10% | -$10.8M |
|
|
37
Revolution Medicines
RVMD
$7.43B
| $95.2M | 0.97% |
3,458,805
+1,604,000
| +86% | +$44.1M |
|
38
Evolent Health
EVH
$1.11B
| $94M | 0.95% |
3,032,678
-605,733
| -17% | -$18.8M |
|
39
Insmed
INSM
$30.3B
| $93.2M | 0.95% |
3,385,645
+264,744
| +8% | +$7.29M |
|
40
HCA Healthcare
HCA
$95.4B
| $82.9M | 0.84% |
341,473
+7,200
| +2% | +$1.75M |
|
41
Nektar Therapeutics
NKTR
$543M
| $82.5M | 0.84% |
4,594,656
+493,252
| +12% | +$8.86M |
|
|
ACCD
42
DELISTED
Accolade, Inc. Common Stock
ACCD
| $78.4M | 0.8% |
1,860,203
+135,504
| +8% | +$5.71M |
|
43
Bristol-Myers Squibb
BMY
$96.7B
| $77.1M | 0.78% |
1,302,934
-160,498
| -11% | -$9.5M |
|
44
Scholar Rock
SRRK
$3.3B
| $75.8M | 0.77% |
2,294,425
-3,200
| -0.1% | -$106K |
|
45
Baxter International
BAX
$12.1B
| $74.3M | 0.75% |
923,223
+22,600
| +3% | +$1.82M |
|
46
Idexx Laboratories
IDXX
$50.7B
| $73.5M | 0.75% |
118,120
| – | – |
|
|
MTEM
47
DELISTED
Molecular Templates, Inc.
MTEM
| $73M | 0.74% |
10,878,003
+1,249,382
| +13% | +$8.38M |
|
48
Centene
CNC
$14.8B
| $71.9M | 0.73% |
1,154,545
-231,752
| -17% | -$14.4M |
|
49
Regeneron Pharmaceuticals
REGN
$59.8B
| $64.4M | 0.65% |
106,410
+750
| +0.7% | +$454K |
|
50
Hologic
HOLX
$14.7B
| $64.3M | 0.65% |
870,662
-43,090
| -5% | -$3.18M |
|